DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma
Talk To Us

Clinical Regulatory

Here you get all the information related to the clinical trials regulatory services, management, and clinical development.

Conducting Clinical Trials for Investigational Products in Brazil

Blogs, Clinical Regulatory /

Brazil is emerging as an attractive location for clinical research as it offers access to a range of patient demographics and medical facilities due to its diverse population and robust healthcare infrastructure. Conducting clinical trials for investigational products is a meticulous and highly regulated process, requiring sponsors to adhere to stringent guidelines. This ensures the […]

Conducting Clinical Trials for Investigational Products in Brazil Read More »

Essential Aspects of Labeling for Clinical Supplies and Investigational Products

Blogs, Clinical Regulatory, Regulatory /

With the expansion of clinical research and development, precise labeling of investigational products is not merely a formality but a critical aspect ensuring the safety, efficacy, and regulatory compliance of clinical trials. Pharmaceutical companies are obliged to follow an integrated approach in labeling considering all aspects of clinical study planning to promote multilingual and multicultural

Essential Aspects of Labeling for Clinical Supplies and Investigational Products Read More »

Assessing COVID-19 Symptoms in Clinical Trials

Blogs, Clinical Regulatory, Regulatory /

The onset of the coronavirus, or COVID-19, created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. Though no longer considered a “public health emergency” (under section 319 of the Public Health Services Act), the virus and its new strains are still actively circulating. This requires rigorous

Assessing COVID-19 Symptoms in Clinical Trials Read More »

Development of CAR T Cell Products

Blogs, Clinical Regulatory, Regulatory /

Chimeric antigen receptor (CAR) T cell products refer to therapeutic human gene therapy products. They involve the genetic modification of T cell specificity which allows them to recognize a specific target antigen for therapeutic use.  CAR T cells are associated with many challenges related to their development, manufacturing, testing, and even clinical evaluation. Therefore, it

Development of CAR T Cell Products Read More »

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products

Clinical Regulatory, Insights, Regulatory /

The field of gene therapy has witnessed significant advancements with the development of genome editing technologies. These technologies allow scientists to break, modify, and edit specific genes in a DNA sequence-specific manner, opening up new possibilities for gene therapy. While traditional gene therapy involves the addition of new genes to human cells or tissue, genome

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products Read More »

Easing Requirements for Minimal Risk Clinical Trials

Blogs, Clinical Regulatory, Regulatory /

Expediting clinical trials that post minimal risk is important to advance healthcare & drug development. In particular, easing the requirements for informed consent regarding trial participants- for minimal risk clinical trials- can help expedite the entire clinical development process and ultimately accelerate the overall regulatory approval process. Earlier the US FDA’s regulations allowed for exceptions

Easing Requirements for Minimal Risk Clinical Trials Read More »

Streamlining Clinical Investigations for Medical Devices

Blogs, Clinical Regulatory, Medical Device, Regulatory /

Clinical investigations for medicinal devices are critical in order to advance healthcare and patient safety. Streamlining clinical investigations help accelerate the delivery of innovative solutions to patients, which ensures timely access to devices that would help diagnose and treat diseases. Simplifying regulatory processes, enhancing stakeholder engagement, and aligning with global practices fosters more rapid approvals.

Streamlining Clinical Investigations for Medical Devices Read More »

The Use of Item Response Theory in Clinical Outcome Assessments

Blogs, Clinical Regulatory, Regulatory /

Clinical outcome assessments (COAs) are a critical component of clinical trials and regulatory submissions for regulatory agencies like the US FDA. The US FDA defines a COA as a “measure that describes or reflects how a patient feels, functions, or survives”; COAs provide important information to the US FDA on the effectiveness of therapies so

The Use of Item Response Theory in Clinical Outcome Assessments Read More »

UK MHRA: Navigating Nuances in Clinical Trial Applications

Blogs, Clinical Regulatory, Regulatory /

The UK Medicines and Healthcare products Regulatory Agency (MHRA) receives approximability 1000 clinical trial authorization (CTA) applications a year. These are for investigational medicinal products of which >95% are approved. However, >50% still need additional information to be submitted in order to get approved. The majority of the requests for additional information, including “grounds for

UK MHRA: Navigating Nuances in Clinical Trial Applications Read More »

Japan PMDA: The Role of In-Country Clinical Caretakers

Blogs, Clinical Regulatory, Regulatory /

Japan has a robust regulatory framework for pharmaceuticals and medical devices, which includes specific requirements for In-Country Clinical Caretakers (ICCC). Foreign manufacturers that wish to penetrate the Japanese market must appoint an ICC, who resides in Japan, to sponsor the clinical trials on their behalf. Thus, they play a crucial part in ensuring that foreign

Japan PMDA: The Role of In-Country Clinical Caretakers Read More »